Avellino

Avellino is a biotechnology and healthcare startup founded in 2008, headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK. The company's slogan, "We turn genetic data into actionable healthcare insights, creating a healthier future for all," reflects its core mission.

Avellino specializes in turning genomic analytics into actionable healthcare insights using artificial intelligence (AI) and machine learning. It has a strong focus on various healthcare specialties, including ophthalmology, oncology, pathogenomics, and infectious diseases.

The company has completed over one million genetic eye tests since 2008 and has commercialized its products in the United States, South Korea, and Japan. Additionally, its CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV.

Avellino's research and development team has made significant discoveries leveraging genetic data, with programs in early detection of oncology, polygenic risk analysis for glaucoma, and siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II, currently in preclinical development.

The company highlights its focus on health equity by prioritizing the inclusion of ethnically diverse populations in its studies to maximize the global impact of its genomics breakthroughs.

As of now, there is no available information on Avellino's last investment or the involved investors.